机构:
Univ Washington, Seattle Qual Life Grp, Seattle, WA 98195 USA
Univ Washington, Biobehav Canc Prevent & Training Program, Seattle, WA 98195 USAMapi, Patient Ctr Outcomes, Lyon, France
Patrick, Donald L.
[2
,3
]
Acquadro, Catherine
论文数: 0引用数: 0
h-index: 0
机构:
Mapi Res Trust, 27 Rue Villette, F-69003 Lyon, FranceMapi, Patient Ctr Outcomes, Lyon, France
Acquadro, Catherine
[4
]
机构:
[1] Mapi, Patient Ctr Outcomes, Lyon, France
[2] Univ Washington, Seattle Qual Life Grp, Seattle, WA 98195 USA
[3] Univ Washington, Biobehav Canc Prevent & Training Program, Seattle, WA 98195 USA
[4] Mapi Res Trust, 27 Rue Villette, F-69003 Lyon, France
Objectives The objectives of this study were to finalize, develop the scoring, and explore the psychometric properties of the ACCEPTance by the Patients of their Treatment (ACCEPT(C)) questionnaire, as well as to provide the first elements for its interpretation and guidance for its future use. Methods ACCEPT(C) was finalized according to reference methods including testing in a pilot study, i.e., a multi-center, observational, longitudinal study conducted in France, in collaboration with a network of pharmacists. Principal component analysis using Varimax rotation was performed. The loadings of items on components in the principal component analysis were used to inform item selection. Validity of the measurement model of ACCEPT(C) was confirmed using Multi-trait/Multi-item Analysis based on item-scale Spearman correlations. Internal consistency reliability of the questionnaire was assessed by determining the Cronbach's alpha coefficient. Linear and logistic regressions were used to identify predictors of general acceptance, and to study predictors of persistence. Results A total of 189 patients were included. The final version of ACCEPT(C) is composed of 25 items, distributed in seven dimensions providing a comprehensive appraisal of acceptance of long-term medication, with six scores measuring acceptance of treatment specific attributes and one score measuring general treatment acceptance. The measurement properties of ACCEPT(C) were overall fairly satisfactory. Regressions showed that Acceptance/Effectiveness is a predictor of general acceptance. However, no predictor of persistence could be identified. Conclusion The self-administered ACCEPT(C) questionnaire is a valid and reliable instrument for the assessment of patients' acceptance of long-term medication. Disease-specific and large prospective studies are needed to assess the ability of ACCEPT(C) to predict persistence with treatment.
机构:
Worldwide Outcomes Research, La Jolla Laboratories, Pfizer Inc., San Diego, CA 92121-1111Worldwide Outcomes Research, La Jolla Laboratories, Pfizer Inc., San Diego, CA 92121-1111
Atkinson M.J.
;
Sinha A.
论文数: 0引用数: 0
h-index: 0
机构:
Quintiles Strategic Research Serv., Quintiles Inc., San Francisco, CAWorldwide Outcomes Research, La Jolla Laboratories, Pfizer Inc., San Diego, CA 92121-1111
Sinha A.
;
Hass S.L.
论文数: 0引用数: 0
h-index: 0
机构:
Worldwide Outcomes Research, Pfizer Inc., San Diego, CA 92121-1111Worldwide Outcomes Research, La Jolla Laboratories, Pfizer Inc., San Diego, CA 92121-1111
Hass S.L.
;
Colman S.S.
论文数: 0引用数: 0
h-index: 0
机构:
Quintiles Strategic Research Serv., Quintiles Inc., San Francisco, CAWorldwide Outcomes Research, La Jolla Laboratories, Pfizer Inc., San Diego, CA 92121-1111
Colman S.S.
;
Kumar R.N.
论文数: 0引用数: 0
h-index: 0
机构:
University of Michigan, College of Pharmacy, Ann Arbor, MIWorldwide Outcomes Research, La Jolla Laboratories, Pfizer Inc., San Diego, CA 92121-1111
Kumar R.N.
;
Brod M.
论文数: 0引用数: 0
h-index: 0
机构:
The BROD GROUP, Mill Valley, CAWorldwide Outcomes Research, La Jolla Laboratories, Pfizer Inc., San Diego, CA 92121-1111
Brod M.
;
Rowland C.R.
论文数: 0引用数: 0
h-index: 0
机构:
Worldwide Outcomes Research, Pfizer Inc., San Diego, CA 92121-1111Worldwide Outcomes Research, La Jolla Laboratories, Pfizer Inc., San Diego, CA 92121-1111
机构:
Univ Calif San Francisco, Ctr AIDS Prevent Studies, Sch Med, San Francisco, CA 94105 USAUniv Calif San Francisco, Ctr AIDS Prevent Studies, Sch Med, San Francisco, CA 94105 USA
机构:
Worldwide Outcomes Research, La Jolla Laboratories, Pfizer Inc., San Diego, CA 92121-1111Worldwide Outcomes Research, La Jolla Laboratories, Pfizer Inc., San Diego, CA 92121-1111
Atkinson M.J.
;
Sinha A.
论文数: 0引用数: 0
h-index: 0
机构:
Quintiles Strategic Research Serv., Quintiles Inc., San Francisco, CAWorldwide Outcomes Research, La Jolla Laboratories, Pfizer Inc., San Diego, CA 92121-1111
Sinha A.
;
Hass S.L.
论文数: 0引用数: 0
h-index: 0
机构:
Worldwide Outcomes Research, Pfizer Inc., San Diego, CA 92121-1111Worldwide Outcomes Research, La Jolla Laboratories, Pfizer Inc., San Diego, CA 92121-1111
Hass S.L.
;
Colman S.S.
论文数: 0引用数: 0
h-index: 0
机构:
Quintiles Strategic Research Serv., Quintiles Inc., San Francisco, CAWorldwide Outcomes Research, La Jolla Laboratories, Pfizer Inc., San Diego, CA 92121-1111
Colman S.S.
;
Kumar R.N.
论文数: 0引用数: 0
h-index: 0
机构:
University of Michigan, College of Pharmacy, Ann Arbor, MIWorldwide Outcomes Research, La Jolla Laboratories, Pfizer Inc., San Diego, CA 92121-1111
Kumar R.N.
;
Brod M.
论文数: 0引用数: 0
h-index: 0
机构:
The BROD GROUP, Mill Valley, CAWorldwide Outcomes Research, La Jolla Laboratories, Pfizer Inc., San Diego, CA 92121-1111
Brod M.
;
Rowland C.R.
论文数: 0引用数: 0
h-index: 0
机构:
Worldwide Outcomes Research, Pfizer Inc., San Diego, CA 92121-1111Worldwide Outcomes Research, La Jolla Laboratories, Pfizer Inc., San Diego, CA 92121-1111
机构:
Univ Calif San Francisco, Ctr AIDS Prevent Studies, Sch Med, San Francisco, CA 94105 USAUniv Calif San Francisco, Ctr AIDS Prevent Studies, Sch Med, San Francisco, CA 94105 USA